exatecan mesylate

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Sarcoma

Conditions

Sarcoma

Trial Timeline

Jan 1, 2003 → Apr 1, 2006

NCT ID

NCT00055952

About exatecan mesylate

exatecan mesylate is a phase 2 stage product being developed by Daiichi Sankyo for Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00055952. Target conditions include Sarcoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00055952	Phase 2	Completed	Jan 1, 2003	Apr 1, 2006	Sarcoma
NCT00055939	Phase 2	Completed	Jan 1, 2003	Apr 1, 2006	Sarcoma
NCT00017212	Phase 2	Completed	Apr 1, 2001	Sep 1, 2003	Esophageal Cancer
NCT00005938	Phase 2	Completed	Mar 1, 2000	Apr 1, 2005	Extrahepatic Bile Duct Cancer
NCT00004866	Phase 2	Completed	Jan 1, 2000	Sep 1, 2003	Cervical Cancer
NCT00004108	Phase 2	Completed	Sep 1, 1999	Apr 1, 2005	Liver Cancer
NCT00004060	Phase 2	Completed	Jul 1, 1999	Sep 1, 2000	Fallopian Tube Cancer
NCT00004046	Phase 2	Completed	Jun 1, 1999	Apr 1, 2002	Breast Cancer
NCT00003951	Phase 2	Completed	Jun 1, 1999	Apr 1, 2005	Pancreatic Cancer
NCT00004045	Phase 2	Completed	Jun 1, 1999	Aug 1, 2001	Prostate Cancer
NCT00004047	Phase 1	Completed	Jun 1, 1999	Apr 1, 2005	Leukemia

Competing Products

20 competing products in Sarcoma

See all competitors

Product	Company	Stage	Hype Score
Tc99m-tilmanocept	Navidea Biopharmaceuticals	Phase 1	25
Azenosertib + Gemcitabine	Zentalis Pharmaceuticals	Phase 1/2	33
Olaratumab + Doxorubicin + Ifosfamide + Mesna	Eli Lilly	Phase 1	33
CAB-AXL-ADC + PD-1 inhibitor	BioAtla	Phase 1/2	33
Abemaciclib	Eli Lilly	Phase 2	52
Abemaciclib + Placebo	Eli Lilly	Phase 3	77
cisplatin + doxorubicin hydrochloride + etoposide + ifosfamide + methotrexate + zoledronic acid	Chugai Pharmaceutical	Phase 3	77
PLX3397 + sirolimus	Daiichi Sankyo	Phase 1/2	41
exatecan mesylate	Daiichi Sankyo	Phase 2	52
efatutazone	Daiichi Sankyo	Phase 2	52
soblidotin	Daiichi Sankyo	Phase 2	52
Linsitinib	Astellas Pharma	Phase 2	52
Fluzoparib+ Dalpiciclib	Sun Pharmaceutical	Phase 2	52
Anlotinib Hydrochloride	Sun Pharmaceutical	Phase 2	52
Doxorubicin Hydrochloride Liposome+Irinotecan + Temozolomide+Irinotecan+Vincristine	Sun Pharmaceutical	Phase 2	52
irinotecan liposome (II) + temozolomide + fluzoparib	Sun Pharmaceutical	Phase 2	52
Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV	Eisai	Phase 3	77
Eribulin	Eisai	Phase 2	52
Lenvatinib + Ifosfamide + Etoposide + Lenvatinib	Eisai	Phase 2	52
Palonosetron - Single Dose + Palonosetron - Triple Dose + Adriamycin + Ifosfamide chemotherapy (AI) + Zinecard + Mesna + Vincristine + Dexamethasone	Eisai	Pre-clinical	23

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved

OAC aloneApproved

olmesartan medoxomil + Placebo + losartan potassiumApproved

Prasugrel + ClopidogrelApproved

Diet+pravastatinApproved